




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification ⁶ : C12N 15/82, 5/10, 9/24, C07K 14/395, 14/415, 14/035, A01H 5/00		A1	(11) International Publication Number: WO 98/59062
			(43) International Publication Date: 30 December 1998 (30.12.98)
(21) International Application Number: PCT/US98/13006		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 23 June 1998 (23.06.98)		<p>Published With international search report. With amended claims.</p> <p style="font-size: 2em; margin-left: 100px;">D1</p>	
(30) Priority Data: 08/881,687 24 June 1997 (24.06.97) US			
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/881,687 (CON) Filed on 24 June 1997 (24.06.97)			
(71) Applicant (for all designated States except US): E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): LIU, Zhan-Bin [CN/US]; 108C Presidential Drive, Greenville, DE 19807 (US). ODELL, Joan, Tellefsen [US/US]; 127 Monitor Place, P.O. Box 826, Unionville, PA 19375 (US).			
(74) Agent: CHRISTENBURY, Lynne, M.; E.I. du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).			
(54) Title: SPECIFIC GENE ACTIVATION BY CHIMERIC GAL4 TRANSCRIPTION FACTORS IN STABLE TRANSGENIC PLANTS			

EXPRESSION OF CHIMERIC Gal4 ACTIVATORS

SEED-SPECIFIC



CONSTITUTIVE



(57) Abstract

A method for regulating gene expression in a stably transformed transgenic plant cell utilizing a Gal4 chimeric transcription factor is described.






INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification ⁶ : C12N 15/82, 5/10, 9/24, C07K 14/395, 14/415, 14/035, A01H 5/00		A1	(11) International Publication Number: WO 98/59062
			(43) International Publication Date: 30 December 1998 (30.12.98)
(21) International Application Number: PCT/US98/13006 (22) International Filing Date: 23 June 1998 (23.06.98) (30) Priority Data: 08/881,687 24 June 1997 (24.06.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/881,687 (CON) Filed on 24 June 1997 (24.06.97) (71) Applicant (for all designated States except US): E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): LIU, Zhan-Bin [CN/US]; 108C Presidential Drive, Greenville, DE 19807 (US). ODELL, Joan, Tellefsen [US/US]; 127 Monitor Place, P.O. Box 826, Unionville, PA 19375 (US). (74) Agent: CHRISTENBURY, Lynne, M.; E.I. du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. With amended claims.	
<div style="font-size: 2em; margin: 0;">D1</div>			
(54) Title: SPECIFIC GENE ACTIVATION BY CHIMERIC GAL4 TRANSCRIPTION FACTORS IN STABLE TRANSGENIC PLANTS			

EXPRESSION OF CHIMERIC Gal4 ACTIVATORS

SEED-SPECIFIC



CONSTITUTIVE



(57) Abstract

A method for regulating gene expression in a stably transformed transgenic plant cell utilizing a Gal4 chimeric transcription factor is described.



PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/00, 15/09, 15/12, 15/29, 15/64, 15/82, A01H 4/00, 5/00	A1	(11) International Publication Number: WO 98/10062 (43) International Publication Date: 12 March 1998 (12.03.98)
(21) International Application Number: PCT/US97/15340 (22) International Filing Date: 2 September 1997 (02.09.97) (30) Priority Data: 08/706,946 3 September 1996 (03.09.96) US (71) Applicant: MONSANTO COMPANY [US/US]; 700 Chesterfield Parkway North, St. Louis, MO 53198-0001 (US). (72) Inventors: BRAR, Gurdip; 1312 Sweeney Drive, Middleton, WI 53562 (US). RUSSELL, David, R.; 6 Sumter Court, Madison, WI 53705 (US). (74) Agent: SEAY, Nicholas, J.; Quarles & Brady, P.O. Box 2113, Madison, WI 53701-2113 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: MONOCOT SEED GENE EXPRESSION SYSTEM		
(57) Abstract A gene construct comprising the rice glutelin-1 promoter operably connected to a foreign non-plant gene is disclosed. A monocot seed containing a gene construct comprising a rice glutelin-1 promoter operably connected to a foreign non-plant gene is also disclosed. Preferably, the gene product is expressed at a level of at least 1 % of total soluble endosperm protein. Most preferably, the gene product is expressed at a level of at least 2.5 % of the total soluble endosperm protein.		

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/00, 15/09, 15/12, 15/29, 15/64, 15/82, A01H 4/00, 5/00		A1	(11) International Publication Number: WO 98/10062 (43) International Publication Date: 12 March 1998 (12.03.98)
(21) International Application Number: PCT/US97/15340 (22) International Filing Date: 2 September 1997 (02.09.97) (30) Priority Data: 08/706,946 3 September 1996 (03.09.96) US (71) Applicant: MONSANTO COMPANY [US/US]; 700 Chesterfield Parkway North, St. Louis, MO 53198-0001 (US). (72) Inventors: BRAR, Gurdip; 1312 Sweeney Drive, Middleton, WI 53562 (US). RUSSELL, David, R.; 6 Sumter Court, Madison, WI 53705 (US). (74) Agent: SEAY, Nicholas, J.; Quarles & Brady, P.O. Box 2113, Madison, WI 53701-2113 (US).			(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: MONOCOT SEED GENE EXPRESSION SYSTEM (57) Abstract A gene construct comprising the rice glutelin-I promoter operably connected to a foreign non-plant gene is disclosed. A monocot seed containing a gene construct comprising a rice glutelin-I promoter operably connected to a foreign non-plant gene is also disclosed. Preferably, the gene product is expressed at a level of at least 1 % of total soluble endosperm protein. Most preferably, the gene product is expressed at a level of at least 2.5 % of the total soluble endosperm protein.			



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification ⁶ : C12N 15/82, 5/10, 9/24, C07K 14/395, 14/415, 14/035, A01H 5/00		A1	(11) International Publication Number: WO 98/59062
		(43) International Publication Date: 30 December 1998 (30.12.98)	
(21) International Application Number: PCT/US98/13006 (22) International Filing Date: 23 June 1998 (23.06.98) (30) Priority Data: 08/881,687 24 June 1997 (24.06.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/881,687 (CON) Filed on 24 June 1997 (24.06.97) (71) Applicant (for all designated States except US): E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): LIU, Zhan-Bin [CN/US]; 108C Presidential Drive, Greenville, DE 19807 (US). ODELL, Joan, Tellefsen [US/US]; 127 Monitor Place, P.O. Box 826, Unionville, PA 19375 (US). (74) Agent: CHRISTENBURY, Lynne, M.; E.I. du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. With amended claims.	

D1

(54) Title: SPECIFIC GENE ACTIVATION BY CHIMERIC GAL4 TRANSCRIPTION FACTORS IN STABLE TRANSGENIC PLANTS

EXPRESSION OF CHIMERIC Gal4 ACTIVATORS

SEED-SPECIFIC



CONSTITUTIVE



(57) Abstract

A method for regulating gene expression in a stably transformed transgenic plant cell utilizing a Gal4 chimeric transcription factor is described.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TITLESPECIFIC GENE ACTIVATION BY CHIMERIC GAL4 TRANSCRIPTION
FACTORS IN STABLE TRANSGENIC PLANTSFIELD OF THE INVENTION

5 The present invention pertains to a method of regulating transgene expression using a two component system and, more particularly, to a system specific for stably transformed plants which comprises 1) a promoter containing Gal4 binding sites and, optionally, additional regulatory elements and 2) a chimeric transcription factor containing a Gal4 DNA binding domain and an activation domain.

BACKGROUND OF THE INVENTION

10 Improvement of crop plants for a variety of traits, including disease and pest resistance, and grain quality improvements such as oil, starch or protein composition, can be achieved by introducing new or modified genes (transgenes) into the plant genome. Expression of genes, including transgenes, is in general controlled by the promoter through a complex set of protein/DNA and protein/protein interactions. Promoters can impart patterns of expression that are either constitutive or limited to specific tissues or times during development. There are limitations in the types of expression achievable using existing promoters for transgene expression. One limitation is in the expression level achievable. It is difficult to obtain traits that require relatively high expression of an introduced gene, due to limitations in promoter strength. A second limitation is that the pattern of expression conferred by the particular promoter employed is inflexible in that the same promoter-dependent pattern of expression is conferred from generation to generation.

20 For imparting certain traits, it is desirable to have the ability to regulate the trait-conferring transgene expression differently in successive generations. One example would be a trait that has a side effect of being detrimental to seed viability, but which is desired in a grain product. For example, one can envision using plant seeds to produce proteins, starches, or other substances in grain (product seeds not used for further planting) which are detrimental to seed viability. In this case it would be desirable to carry the trait-conferring transgene in an inactive state in breeding lines up until the time of grain production. Then a new type of expression system is required to activate the trait gene in the grain.

25 Another limitation in the current methods of transgene expression is an inability to coordinately regulate multiple transgenes in transgenic crops. Multiple copies of the same promoter, directing coordinate regulation of multiple genes, can lead to gene inactivation through repeat induced gene silencing (Ye and Signer, 1996, Proc. National Acad. Sci. 93:10881-10886) or other means of cosuppression. Thus, a means of coordinately regulating multiple transgenes is desirable.

30 Transcriptional activation is primarily mediated through transcription factors that interact with enhancer and promoter elements. Binding of transcription factors to such DNA

elements constitutes a crucial step in transcriptional initiation. Structural and functional analyses of transcription factors revealed that many of these proteins have a modular protein structure, i.e., they are often modular, made up of a specific DNA-binding domain and a separate and independently acting activation domain. Researchers have found that

5 heterogeneous domains can be combined, the resultant composite activators being functional in mammalian cells. An example of such an activator is the protein produced by fusion of the Gal4 DNA-binding domain with the activation domain of VP16.

Each transcription factor binds to its specific binding sequence in a promoter and activates expression of the linked coding region through interactions with coactivators

10 and/or proteins that are a part of the transcription complex. A DNA binding domain and an activation domain derived from different proteins can be linked to produce a chimeric transcription factor. One transcription factor that has been studied is the yeast transcription factor Gal4 which is composed of a DNA binding domain and an activation domain. Native Gal4, a protein of 881 amino acids, is a transcriptional activator of genes required for

15 galactose catabolism in the yeast *S. cerevisiae*. The protein binds specifically to the upstream activating sequence called UAS_G and activates transcription of the divergently transcribed genes GAL1 and GAL10.

A two component transcription factor/target promoter system could be used to address the above limitations of transgene expression with existing promoters. For example, a

20 chimeric transcription factor comprising the Gal4 DNA binding domain could be used as the basis of a two component gene expression system. In fact, chimeric transcription factors containing the Gal4 DNA binding domain and various activation domains have been successfully used in plant cells in transient assays, but not in stable transformants.

The yeast Gal4 DNA binding domain fused to one or two of its own activation

25 domains was able to activate expression of a chloramphenicol acetyl transferase (CAT) reporter gene, with Gal4 binding sites in the promoter, in a transient assay in tobacco protoplasts (Ma et al., 1988 Nature 334, p 631-633). The expression level was similar to that directed by the CaMV 35S promoter. A chimeric transcription factor composed of the Gal4 DNA binding domain and an *E. coli* DNA fragment-encoded activation domain also

30 activated expression.

A chimeric transcription factor composed of the Gal4 DNA binding domain and the proline-rich activation domain of GBF1, a G-box binding transcription factor of *Arabidopsis thaliana* activated expression of a luciferase reporter gene with Gal4 binding sites in the promoter when tested in a transient assay using soybean cell culture protoplasts (Schindler et

35 al., 1992 EMBO J 11 p 1275-1289). Activated expression was less than that conferred by the Gal4/*E. coli* activation domain factor. No activation by the intact Gal4 protein was observed, which was speculated to be due to possible inefficient translation or protein instability.

A chimeric transcription factor composed of the Gal4 DNA binding domain and the activation domain of PvAlf, a seed-specific transcription factor of *Phaseolus vulgaris*, activated expression of a CAT reporter gene, with Gal4 binding sites in the promoter, in a transient assay in bean cotyledon cells (Bobb et al., 1995 Plant J 8 p 101-113).

5 No effect of the Gal4 DNA binding domain was detected in stably transformed tobacco plants containing GUS and NPTII reporter genes with Gal4 sites in their promoters (Reuchek et al., 1995 Plant Cell Reports 14 p 773-776). No expression of the Gal4 DNA binding domain protein was detected.

10 Canadian Patent Application Number 2,150,039, which was published on August 9, 1996, describes a method to control the expression of genes in transgenic plants using native Gal4 as the transactivator. Specifically, it discloses an example in which a GUS reporter gene with Gal4 sites in its promoter is targeted by Gal4 protein expressed from the constitutive CaMV 35S promoter. These two components were co-introduced into *Arabidopsis* root cells and leaf tissue growing from callus cultures was assayed. When this
15 leaf material was stained for GUS only the veins were positive for expression of the reporter activity. These results are inconsistent with the expectation of constitutive expression throughout the leaf and in all tissues. In other words, the expected result was that the expression of GUS should have been indistinguishable from the example of GUS expressed directly from the 35S promoter (Benfey et al., EMBO J 9:1685-1696 (1990); Odell et al.,
20 Nature 313: 810-812 (1985)). Thus, it is likely that the expression which was detected only in the veins is due not to the functioning of the described system controlled by the 35S promoter. Expression in the veins may be due to integration of GUS adjacent to an endogenous regulatory sequence that directs expression in the veins (Sundaresan et al., 1995, Genes & Development 9:1797-1810; Topping et al., 1994 Plant J. 5:895-903), or to
25 background expression from the promoter operably linked to the GUS coding region. There is no indication that the Gal4 transactivator is expressed and functioning to regulate GUS expression, since it is co-introduced and not added separately to activate the Gal4 site promoter. This result indicates the failure of the transactivation system with Gal4, as was found by other researchers, as discussed above.

30 While it is known that Gal4 chimeric transcription factor/target promoter systems can function in plant cells in transient assays, there are only reports of failed or inconclusive attempts to use this type of system in stably transformed plants. Thus, there is still a need for a two component system to regulate transgene expression. If such a system was available, then other techniques such as those described in PCT Application having
35 International Publication Number WO 92/08341 which was published on May 29, 1992, the disclosure of which is hereby incorporated by reference, could be used to induce expression of the trait gene only in the production field. In other cases, a two-component system may be used to amplify the expression level from a promoter with desirable tissue or cell type

specificity, while maintaining the desired tissue or cell type specificity. Also a two-component system may be used to coordinately regulate multiple transgenes. Still further, an expression system that achieves levels of expression not previously obtained with known promoters is desirable for traits wherein high levels of protein products are required to achieve the traits such as the expression of a protein having a high lysine and/or methionine content which in turn then can improve seed amino acid composition.

SUMMARY OF THE INVENTION

This invention concerns a method for regulating gene expression in a stably transformed transgenic plant cell which comprises combining into the genome of the plant cell:

- a) a first chimeric gene comprising in the 5' to 3' direction:
 - (1) a promoter operably linked to at least one Gal4 binding sequence;
 - (2) a coding sequence or a complement thereof operably linked to the promoter; and
 - (3) a polyadenylation signal sequence operably linked to the coding sequence or a complement thereof; provided that when the promoter is a minimal promoter then the Gal4 binding sequence is located upstream of the minimal promoter; and
- b) a second chimeric gene comprising in the 5' to 3' direction:
 - (1) a promoter;
 - (2) a DNA sequence encoding a DNA binding domain of a Gal4 transcriptional activator;
 - (3) a DNA sequence encoding a transcriptional activation domain operably linked to the DNA sequence of (2); and
 - (4) a polyadenylation signal sequence operably linked to the DNA sequence of (3);

wherein the expression of the second chimeric gene regulates expression of the first chimeric gene.

In another aspect, the first gene further can comprise at least one regulatory element.

BRIEF DESCRIPTION OF FIGURES AND SEQUENCES LISTINGS

The file of this patent contains at least one drawing executed in color. Copies of this patent with color drawing(s) will be provided by the Patent and Trademark Office upon request and payment of the necessary fee.

Figure 1 is a map of plasmid pG4G which contains the chimeric G4G gene in pGEM9Zf. The G4G gene consists of 4 Gal4 binding sites, the -65 phaseolin promoter

region and leader, the GUS coding region, and a phaseolin 3' polyadenylation signal sequence region.

Figure 2 is a map of plasmid pPhG4G. This is a modified form of pG4G; it has an additional sequence from the 5' upstream region of the phaseolin promoter that was added upstream of the G4G gene.

Figure 3 is a diagram which compares the synthetic promoters used in the present study, and which represent combinations between Gal4 elements with other regulatory elements.

Figure 4 is a map of plasmid pPh/P-G4Alf. This is plasmid pUC18 into which the chimeric Ph/P-Gal4-PvAlf gene has been inserted. The chimeric gene consists of the phaseolin promoter and leader, the Gal4 DNA binding domain (BD), the PvAlf activation domain (AD), and the phaseolin 3' signal sequence region.

Figure 5 is a map of plasmid p35S-G4Alf. This is plasmid pUC18 into which the chimeric p35S-Gal4-PvAlf gene has been inserted. The chimeric gene is as that shown in Figure 3 but with substitution of the 35S promoter and chlorophyll a/b binding protein leader for the phaseolin promoter.

Figure 6 is a map of pPh/P-G4VP16. This is plasmid pUC18 into which the chimeric Ph/P-Gal4-VP16 gene has been inserted. The chimeric gene is as that shown in Figure 3 but with substitution of the VP16 activation domain for the PvAlf activation domain.

Figure 7 is a map of plasmid p35S-G4VP16. This is plasmid pUC18 into which the chimeric p35S-Gal4-VP16 gene has been inserted. The gene is as that shown in Figure 4 but with substitution of the VP16 activation domain for the PvAlf activation domain.

Figure 8 depicts the different expression cassettes encoding chimeric Gal4 activators that are used in this work.

Figure 9 presents the results of fluorometric assays demonstrating specific activation of the GUS reporter gene from pZBL3 by the chimeric transactivator Ph/P-G4VP16 in transgenic tobacco seeds. Genetic crosses were made between different reporter lines (pZBL2 2C, 11A, 4B; pZBL3 2A, 6A, 4B, 3D) and different Ph/P-G4VP16 effector lines (14A, 15A, and 13B).

Figure 10 presents the results of fluorometric assays demonstrating specific activation of the GUS reporter gene from pZBL3 by the chimeric transactivator 35S-G4VP16 in transgenic tobacco seeds. Genetic crosses were made between different reporter lines (pZBL2 2C, 11A, 4B; pZBL3 2A, 6A, 4B, 3D) and different 35S-G4VP16 effector lines (12A, 5A, and 20A).

Figure 11 presents the results of fluorometric assays demonstrating specific activation of the GUS reporter gene from pZBL3 by Ph/P-G4Alf in transgenic tobacco seeds. Genetic crosses were made between different reporter lines (pZBL2 2C, 11A, 4B; pZBL3 2A, 6A, 4B, 3D) and different Ph/P-G4Alf effector lines (17A, 14A, and 3B).

Figure 12 presents the results of fluorometric assays demonstrating specific activation of the GUS reporter gene from pZBL3 by 35S-G4Alf in transgenic tobacco seeds. Genetic crosses were made between different reporter lines (pZBL2 2C, 11A, 4B; pZBL3 2A, 6A, 4B, 3D) and different 35S-G4Alf effector lines (1A, 4A, and 1B).

5 Figure 13 presents the results of fluorometric assays demonstrating specific activation of the GUS reporter genes from pZBL5 and pZBL6 by Ph/P-G4VP16 in transgenic tobacco seeds. Genetic crosses were made between different reporter lines (pZBL5 3F, 2C, 1E; pZBL6 3B, 4F, 8E) and different Ph/P-G4VP16 effector lines (14A, 15A, and 13B). One highly expressed transgenic line containing -410Ph/P-GUS was used as
10 a control, giving a high level of seed-specific expression. One highly expressed transgenic line of 35S-GUS was also used as a control.

Figure 14 presents the results of fluorometric assays demonstrating specific activation of the GUS reporter genes from pZBL5 and pZBL6 by 35S-G4VP16 in transgenic tobacco seeds. Genetic crosses were made between different reporter lines (pZBL5 3F, 2C,
15 1E; pZBL6 3B, 4F, 8E) and different 35S-G4VP16 effector lines (12A, 5A and 20A). One highly expressed transgenic line containing -410Ph/P-GUS was used as a control, giving a high level of seed-specific expression. One highly expressed transgenic line of 35S-GUS was also used as a control.

Figure 15 presents the results of fluorometric assays demonstrating specific
20 activation of the GUS reporter genes from pZBL5 and pZBL6 by Ph/P-G4Alf in transgenic tobacco seeds. Genetic crosses were made between different reporter lines (pZBL5 3F, 2C, 1E; pZBL6 3B, 4F, 8E) and different Ph/P-G4Alf effector lines (17A, 14A and 3B). One highly expressed transgenic line containing -410Ph/P-GUS was used as a control, giving a high level of seed-specific expression. One highly expressed transgenic line of 35S-GUS
25 was also used as a control.

Figure 16 presents the results of fluorometric assays demonstrating specific activation of the GUS reporter genes from pZBL5 and pZBL6 by 35S-G4Alf in transgenic tobacco seeds. Genetic crosses were made between different reporter lines (pZBL5 3F, 2C,
30 1E; pZBL6 3B, 4F, 8E) and different 35S-G4Alf effector lines (1A, 4A and 1B). One highly expressed transgenic line containing -410Ph/P-GUS was used as a control, giving a high level of seed-specific expression. One highly expressed transgenic line of 35S-GUS was also used as a control.

Figure 17 presents the results of fluorometric assays demonstrating specific
35 activation of the GUS reporter genes from pZBL7, pZBL8, pZBL9 and pZBL10 by Ph/P-G4VP16 in transgenic tobacco seeds. Genetic crosses were made between different reporter lines (pZBL7 1A; pZBL8 4A, 1D; pZBL9 3F, 4F, 7A; and pZBL10 11H, 6D, 7C) and different Ph/P-G4VP16 effector lines (14A, 15A, and 13B). One highly expressed transgenic line containing -410Ph/P-GUS was used as a control, giving a high level of seed-

specific expression. One highly expressed transgenic line of 35S-GUS was also used as a control.

Figure 18 presents the results of fluorometric assays demonstrating specific activation of the GUS reporter genes from pZBL7, pZBL8, pZBL9 and pZBL10 by 35S-G4VP16 in transgenic tobacco seeds. Genetic crosses were made between different reporter lines (pZBL7 1A; pZBL8 4A, 1D; pZBL9 3F, 4F, 7A; and pZBL10 11H, 6D, 7C) and different 35S-G4VP16 effector lines (12A, 5A, and 20A). One highly expressed transgenic line containing -410Ph/P-GUS was used as a control, giving a high level of seed-specific expression. One highly expressed transgenic line of 35S-GUS was also used as a control.

Figure 19 presents the results of fluorometric assays demonstrating specific activation of the GUS reporter genes from pZBL7, pZBL8, pZBL9 and pZBL10 by Ph/P-G4Alf in transgenic tobacco seeds. Genetic crosses were made between different reporter lines (pZBL7 1A; pZBL8 4A, 1D; pZBL9 3F, 4F, 7A; and pZBL10 11H, 6D, 7C) and different Ph/P-G4Alf effector lines (17A, 14A, and 3B). One highly expressed transgenic line containing -410Ph/P-GUS was used as a control, giving a high level of seed-specific expression. One highly expressed transgenic line of 35S-GUS was also used as a control.

Figure 20 presents the results of fluorometric assays demonstrating specific activation of the GUS reporter genes from pZBL7, pZBL8, pZBL9 and pZBL10 by 35S-G4Alf in transgenic tobacco seeds. Genetic crosses were made between different reporter lines (pZBL7 1A; pZBL8 4A, 1D; pZBL9 3F, 4F, 7A; and pZBL10 11H, 6D, 7C) and different 35S-G4Alf effector lines (1A, 4A, and 1B). One highly expressed transgenic line containing -410Ph/P-GUS was used as a control, giving a high level of seed-specific expression. One highly expressed transgenic line of 35S-GUS was also used as a control.

Figure 21 presents the results of fluorometric assays demonstrating specific activation of the GUS reporter genes from -65-GUS and PhG4G by 35S-G4Alf or 35S-G4VP16 in transgenic tobacco seedlings. Genetic crosses were made between different reporter lines (-65-GUS 5C, PhG4G 17C, 5A) and different 35S-G4Alf lines (1A, 1B, 4A) or 35S-G4VP16 effector lines (12A, 5A, 21A, and 20A). One highly expressed transgenic line containing 35S-GUS was used as a control, giving a high level of constitutive gene expression.

SEQ ID NO:1 is the consensus sequence for a Gal4 binding site.

SEQ ID NOS:2-6 are the sequences of the naturally occurring Gal4 binding sites as found in the promoters of genes for galactose catabolism in *Saccharomyces cerevisiae*.

SEQ ID NO:7 is the core sequence of the RY-G-box-RY element used in Example 3.

SEQ ID NO:8 is the sequence of the CACA box found in the glycinin 2 promoter.

SEQ ID NO:9 is the sequence of the legumin box element.

SEQ ID NOS:10-12 are sequences of known variations of the RY box in the promoters of different legumin and glycinin genes.

SEQ ID NO:13 is the core sequence of the Gy2 element used in Example 4.

5 VP1. SEQ ID NOS:14-16 are DNA segments known to confer responsiveness to ABA and

SEQ ID NO:17 is core sequence of the Em regulatory element used in Example 5.

SEQ ID NO:18 is the core sequence of the C1 regulatory element used in Example 6.

SEQ ID NO:19 is the G-box regulatory element used in Example 7.

10 element used in Example 8. SEQ ID NOS:20 and 21 are the critical components of the CHS Unit I regulatory

SEQ ID NO:22 is the CHS Unit I used in Example 7.

SEQ ID NOS:23 and 24 are the oligonucleotides used to form the Gal4 binding site cassette described in Example 1.

15 SEQ ID NOS:25 and 26 are the oligonucleotides used to form the seed-specific RY-G-box-RY regulatory element cassette described in Example 3.

SEQ ID NOS:27 and 28 are the oligonucleotides used to form the glycinin 2 regulatory element cassette described in Example 4.

SEQ ID NOS:29 and 30 are the oligonucleotides used to form the Em regulatory element cassette described in Example 5.

20 SEQ ID NOS:31 and 32 are the oligonucleotides used to form the C1 regulatory element cassette described in Example 6.

SEQ ID NOS:33 and 34 are the oligonucleotides used to form the constitutive G-box regulatory element cassette described in Example 7.

25 SEQ ID NOS:35 and 36 are the oligonucleotides used to form the CHS Unit I regulatory element cassette described in Example 8.

BIOLOGICAL DEPOSIT

The following plasmid has been deposited under the terms of the Budapest Treaty with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, MD 20852, and bears the following accession number:

30

<u>Plasmid</u>	<u>Accession Number</u>	<u>Date of Deposit</u>
pZBL1	ATCC 209128	June 24, 1997

DETAILED DESCRIPTION OF THE INVENTION

35 The term "essentially similar" refers to nucleic acid fragments wherein changes in one or more nucleotide bases do not substantially effect the function of the nucleic acid fragment in binding of the DNA binding domain. "Essentially similar" also refers to a modification in one or more nucleotide bases that results in substitution of one or more amino acids, but does not affect the functional properties of the protein encoded by the DNA sequence. Thus

“essentially similar” amino acid sequences are those that specify proteins having equivalent function. It is therefore understood that the invention encompasses more than the specific exemplary sequences.

5 The term “gene” refers to a nucleic acid fragment that expresses a specific protein or functional RNA, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. “Chimeric gene” refers to any gene that comprises regulatory and coding sequences that are not found together in nature, or sequences encoding parts of proteins not naturally adjoined, or parts of promoters that are not naturally adjoined. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature. “Endogenous gene” refers to a native gene in its natural location in the genome of an organism. A “foreign” gene refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes. A “transgene” is a gene that has been introduced into the genome by a transformation procedure.

20 “Coding sequence” refers to a DNA sequence that codes for a specific amino acid sequence. “Regulatory sequences” refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences include promoters, translation leader sequences, introns, and polyadenylation signal sequences.

25 “Promoter” refers to a DNA sequence involved in controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. “Promoter” includes a minimal promoter that is a short DNA sequence comprised of a TATA-box and other sequences that serve to specify the site of transcription initiation, to which regulatory elements are added for control of expression. “Promoter” also refers to a nucleotide sequence that includes a minimal promoter plus regulatory elements that is capable of controlling the expression of a coding sequence or functional RNA. This type of promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers. Accordingly, an “enhancer” is a DNA sequence which can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a promoter.

35 Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development,

or in response to different environmental conditions. Promoters which cause a gene to be expressed in most cell types at most times are commonly referred to as "constitutive promoters". New promoters of various types useful in plant cells are constantly being discovered; numerous examples may be found in the compilation by Okamuro and
5 Goldberg, *Biochemistry of Plants* 15:1-82, 1989. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, DNA fragments of different lengths may have identical promoter activity.

"Regulatory element" refers to a DNA sequence that plays a role in determining promoter activity, i.e., a regulatory element can play a role in determining the activity of a
10 regulatory sequence. Regulatory elements may affect the level, tissue/cell type specificity and/or developmental timing of expression. A "regulatory element" may be a part of a promoter, or it may be located upstream of a minimal promoter. DNA sequences considered to be regulatory elements include sequences that have been shown to be target sites for binding of transcription factors, as well as sequences whose properties have not yet been
15 defined but are known to have a function because their deletion from a promoter affects the expression. "Constitutive" regulatory elements are those that direct expression in most tissues of the plant, throughout most of the plant developmental cycle. "Seed-specific" regulatory elements are those that direct expression in seed tissue during seed development. There are different types of seed-specific regulatory elements that may direct expression in
20 different types of seed tissues or at different stages of seed development.

The "translation leader sequence" refers to a DNA sequence located between the promoter sequence of a gene and the coding sequence. The translation leader sequence is present in the fully processed mRNA upstream of the translation start sequence. The translation leader sequence may affect processing of the primary transcript to mRNA,
25 mRNA stability or translation efficiency. (Turner, R. and Foster, G.D. (1995) *Molecular Biotechnology* 3:225).

The "3' non-coding sequences" refer to DNA sequences located downstream of a coding sequence and include polyadenylation signal sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The
30 polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The use of different 3' non-coding sequences is exemplified by Ingelbrecht et al., *Plant Cell* 1:671-680, 1989.

The term "operably linked" refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other. For
35 example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.

A "functional RNA" refers to an antisense RNA, ribozyme, or other RNA that is not translated.

The term "expression", as used herein, refers to the transcription of sense (mRNA) or antisense RNA. Expression also refers to translation of mRNA into a polypeptide.

5 As used herein "Gal4 binding site" means the nucleotide sequence shown in SEQ ID NO:1, or any essentially similar sequences to which the Gal4 DNA binding domain can bind. In other words, the terms "Gal4 binding site" and "Gal4 binding sequence" are used interchangeably herein.

10 CGGAGGACAGTCCTCCG (SEQ ID NO:1)

The Gal4 binding sequence is the consensus sequence of the four Gal4 sites found in the Upstream Activation Sequence (UAS_G) controlling expression of the yeast GAL1 and GAL10 genes and the one Gal4 site found in the GAL7 promoter (Giniger et al., (1985) Cell
15 40:767-774). The original Gal4 site sequences are presented in SEQ ID NOS:2-6.

CGGATTAGAAGCCGCCG (SEQ ID NO:2)

20 CGGGTGACAGCCCTCCG (SEQ ID NO:3)

AGGAAGACTCTCCTCCG (SEQ ID NO:4)

CGCGCCGCACTGCTCCG (SEQ ID NO:5)

25 CGGACAACGTGTGACCG (SEQ ID NO:6)

These different sequences demonstrate some of the variation that can be made in the Gal4 binding site while maintaining the ability of Gal4 to bind, and would be considered essentially similar sequences.

30 As used herein "Gal4 binding site promoter" refers to a promoter that is operably linked to at least one Gal4 site. Thus "Gal4 binding site promoter" may include combinations such as, but not limited to, at least one Gal4 binding sequence and a minimal promoter, at least one Gal4 binding sequence and additional regulatory elements with a minimal promoter, a promoter with at least one Gal4 binding sequence added, or a promoter
35 with at least one Gal4 binding sequence and additional regulatory elements added.

As used herein, "activation domain" refers to a protein domain that has a stimulatory effect on transcription. Natural activation domains are portions of transcription factors that can be fused to DNA binding domains and shown to have transcription stimulatory effects. Natural activation domains can be altered, wherein amino acids are substituted or deleted,
40 without altering the transcription stimulatory effects (Cress and Triezenberg, 1991, Science 251:87-90; Drysdale et al., 1995, Molecular and Cellular Biology 15:1220-1233).

“Transformation” refers to the transfer of a nucleic acid fragment into the genome of a host organism, resulting in genetically stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as “transgenic” organisms. Examples of methods of plant transformation include Agrobacterium-mediated transformation (De Blaere et al. (1987) Meth. Enzymol. 143:277) and particle-accelerated or “gene gun” transformation technology (Klein et al. (1987) Nature (London) 327:70-73; U.S. Pat. No. 4,945,050).

This invention provides for the first time a Gal4 chimeric transcription factor/target promoter system which functions in stably transformed plants. Specifically, the present invention concerns a method of regulating gene expression in a stably transformed transgenic plant cell which comprises combining into the genome of the plant cell:

a) a first chimeric gene comprising in the 5' to 3' direction:

- (1) a promoter operably linked to at least one Gal4 binding sequence;
- (2) a coding sequence or a complement thereof operably linked to the promoter; and
- (3) a polyadenylation signal sequence operably linked to the coding sequence or a complement thereof;

provided that when the promoter is a minimal promoter then the Gal4 binding sequence is located upstream of the minimal promoter; and

b) a second chimeric gene comprising in the 5' to 3' direction:

- (1) a promoter;
- (2) a DNA sequence encoding a DNA binding domain of a Gal4 transcriptional activator;
- (3) a DNA sequence encoding a transcriptional activation domain operably linked to the DNA sequence of (2); and
- (4) a polyadenylation signal sequence operably linked to the DNA sequence of (3);

wherein the expression of the second chimeric gene regulates expression of the first chimeric gene.

In another aspect, the first gene further can comprise at least one regulatory element.

The Gal4 binding site promoter in the first chimeric gene will be activated in the presence of the chimeric transcription factor produced by the second chimeric gene. It is well known in the art that the presence of multiple copies of a DNA binding site in a promoter can increase the effectiveness of the promoter (Carey et al., 1990 Nature 345: 361). Thus, the Gal4 binding site promoter in the first chimeric gene comprises at least one Gal4 binding site having the sequence set forth in SEQ ID NO:1, or a sequence that is essentially similar. The second chimeric gene which encodes the chimeric transcription factor comprises the sequence encoding the DNA binding domain of Gal4, which includes at least the amino terminal 147 amino acids of the Gal4 protein, or an essentially similar sequence.

The activation domain can be any sequence of amino acids that is capable of stimulating transcription. The activation domain is generally derived from a transcription factor or coactivator and is that portion of the protein that interacts with other proteins involved in transcription, thereby stimulating the transcription process. Thus, any activation domain which is capable of stimulating transcription can be used to practice the invention. The preferred activation domain should be an acidic transcriptional activation domain. Such activation domains can include, but are not limited to, those from the herpes simplex virus VP16 protein (Triezenberg et al., 1988 *Genes Dev.* 2: 718) and from the *Phaseolus vulgaris* PvAlf protein (Bobb et al., 1995 *The Plant Journal* 8: 101). Any plant cells, that can currently be transformed or will be transformable in the future, for example dicot or monocot cells, can be used to practice the present invention. Examples of dicot cells include, but are not limited to, cells from soybean, tomato, potato, tobacco, oilseed rape, sunflower, cotton, alfalfa, pea, sugarbeet, chick pea, lentil, lupin, french bean, lima bean. Examples of monocot cells include, but are not limited to, cells from maize, wheat, rye, barley, rice, sorghum.

A first chimeric gene comprising a Gal4binding site promoter and a second chimeric gene encoding a chimeric Gal4 DNA binding domain/activation domain transcription factor can be introduced into the genome of plant cells using techniques well known to those skilled in the art. These methods include, but are not limited to, (1) direct DNA uptake, such as particle bombardment or electroporation (Klein et al. (1987) *Nature (London)* 327:70-73; U.S. Pat. No. 4,945,050), and (2) *Agrobacterium*-mediated transformation (De Blaere et al. (1987) *Meth. Enzymol.* 143:277).

The first chimeric gene comprising a Gal4binding site promoter operably linked to a gene of interest and the second chimeric gene comprising a Gal4 DNA binding domain/activation domain transcription factor are two separate components used to practice the invention. Each of these chimeric genes can be separately transformed into the genome of a plant species such that transformants harboring one component are distinct from transformants harboring the second component. The two components can then be combined into the genome of one plant by genetic crossing of the two transformants harboring the two separate components. Thus, the first and second chimeric genes can be combined into the genome of the plant cell by (a) transforming a plant cell with the first construct, (b) transforming a second plant cell with the second construct, (c) growing fertile mature plants from the transformed plant cells in (a) and (b) and (d) genetically crossing the transformed plants to produce progeny whose genome contains the first and second constructs.

Alternatively, the two components may be introduced together into the same genome by transformation of both components at the same time in the same cell. Still another means is for one component alone to be transformed into the genome, followed by a second

transformation with the second component of the cells already harboring the first component.

Accordingly, in another aspect, this invention concerns plants transformed using the method of the invention and seeds obtained from such plants.

5 For the purpose of regulating transcription of a transgene containing the Gal4 binding site promoter, this promoter is operably linked to an untranslated leader, a coding region, a 3' untranslated sequence, and a polyadenylation signal sequence. Alternatively, the coding region may be replaced by a sequence that produces a functional RNA that may, in turn, mediate control of gene expression by antisense, co-suppression or other gene
10 expression technology.

The chimeric Gal4 DNA binding domain/activation domain transcription factor may be regulated by any constitutive, tissue-specific, or developmentally regulated promoter. This transcription factor in turn regulates expression of a transgene containing the Gal4 binding site promoter, i.e., a promoter operably linked to at least one Gal4 binding sequence.
15 The Gal4 binding site promoter minimally contains at least one Gal4 binding site and a TATA box. Additional elements may be present in the Gal4 binding site promoter, such as a CAAT box, or binding sites for one or more transcription factors other than the chimeric Gal4 DNA binding domain/activation domain transcription factor. It is known in animal systems that targeting of some combinations of transcription factors to the same promoter
20 may produce synergistic effects on the expression level (Lin et al., 1990 Nature 345: 359).

Further enhancement of gene activation by the instant two component system can be obtained by the addition of other regulatory elements in the Gal4 binding site promoter or upstream of a minimal promoter. Such additional regulatory elements can be, but are not limited to, seed-specific elements, constitutive elements, and enhancers. A variety of
25 elements that are involved in regulating expression of genes during seed development have been identified. For example, the RY-G-box-RY regulatory element is commonly found in seed storage protein and lectin gene promoters and is necessary for positive regulation of seed-specific gene expression in the soybean glycinin and β -conglycinin seed storage protein promoters, and the French bean β -phaseolin seed storage protein promoter (Lelievre et al.,
30 1992, Plant Physiol. 98: 387-391; Bustos et al., 1991 EMBO J. 10: 1469-1479; Kawagoe et al., 1994 Plant J. 5: 885-890; Bobb et al., 1997 Nucleic Acids Research 25: 641-647; Dickinson et al., 1988, Nucleic Acids Research 16: 371; Fujiwara and Beachy 1994, Plant Molecular Biology 24: 261-272; Chamberland et al., 1992, Plant Molecular Biology 19: 937-949). The sequences of the RY-G-box-RY elements that are found in different natural
35 promoters have variations, but can be recognized by the presence of particular nucleotide sequences: CATGCAW (the "RY" feature) and CACGTG (the "G-box"). One or more copies of the RY-G-box-RY element, shown in SEQ ID NO:7, or of sequence that is

essentially similar, can be introduced in the Gal4 binding site promoter or upstream of a minimal promoter to increase the level of seed-specific gene expression in plants.

CATGCATGTCTACACGTGATCGCCATGCAA (SEQ ID NO:7)

5

The glycinin 2 (Gy2) regulatory element from the soybean glycinin 2 gene promoter contains both a CACA element and a legumin box, and is required for the high level seed-specific gene expression of this promoter (Lelievre et al., 1992, Plant Physiol. 98: 387-391). The nucleotides that are recognized as the CACA and legumin box elements are presented in

10 SEQ ID NOS:8 and 9, respectively.

TAACACA (SEQ ID NO:8)

TTCCATAGCCATGCATACTGAATGTCT (SEQ ID NO:9)

15

In promoters of different legumin and glycinin genes there are variations in the RY box of the legumin box. Examples are shown in SEQ ID NOS:10-12 (Dickinson et al., 1988, Nucleic Acids Res. 16:371).

20 CATGCATG (SEQ ID NO:10)

CATGCAAG (SEQ ID NO:11)

CATGCATA (SEQ ID NO:12)

25

One or more copies of the Gy2 element, as shown in SEQ ID NO:13, or of sequence that is essentially similar, can also be used in combination with the Gal4 binding sites to increase the level of seed-specific gene expression in plants.

30 TAACACACAAGGCTTCCATAGCCATGCATACTGAAGAATGTCT (SEQ ID NO:13)

The Em regulatory element, including Em1a, Em2 and Em1b elements from the wheat Em gene promoter, is strongly linked to regulation by abscissic acid (ABA) and to the maize transcription factor VP1 in transient assays with maize protoplasts (Marcotte et al., 1989, Plant Cell 1: 969-976; Vasil et al., 1995, Plant Cell 7: 1511-1518). Both ABA and VP1 are involved in regulating expression of genes during seed development. The nucleic acid segments that are recognized as the ABA and VP1 responsive elements are shown in SEQ

35

ID NOS:14-16.

40 GGACACGTGGC (SEQ ID NO:14)

CGAGCAGGC (SEQ ID NO:15)

GCACACGTGCC

(SEQ ID NO:16)

One or more copies of the Em element as shown in SEQ ID NO:17, or of sequence that is essentially similar, can also be used in combination with the Gal4 binding sites to increase the level of seed-specific gene expression in plants.

GGACACGTGGCGCGACAGCAGGGACAACGAGCAGGCCGACGCACGTCCGCGTC
GCTGCACACGTGCC

(SEQ ID NO:17)

The C1 regulatory element, including the GT element and the SphI element from the maize C1 gene promoter, is essential for ABA regulation and VP1 trans-activation (Hattori et al., 1992, *Gene & Development* 6: 609-618; Kao et al., 1996, *Plant Cell* 8: 1171-1179). One or more copies of the C1 element, as shown in SEQ ID NO:18, or of sequence that is essentially similar, can also be used in combination with the Gal4 binding sites to increase the level of seed-specific gene expression in plants.

GTGTCGTGTCGTCCATGCATGCAC

(SEQ ID NO:18)

The G-box (CACGTG) is a hexameric element found in many diverse plant gene promoters. There are many different kinds of G-box binding factors with different binding specificities and affinities to their target sites. The sequences flanking the ACGT core affect the binding specificity of the G-box binding factors (Menkens et al., 1995, *TIBS* 20: 506-510; Katagiri and Chua, 1992, *Trends in Genetics* 8: 22-27; Foster and Chua, 1994, *FASEB* 8: 192-200). One or more copies of the DNA segment containing a G-box motif, as shown in SEQ ID NO:19, or a sequence that is essentially similar, can be used in combination with the Gal4 binding sites to increase the level of constitutive gene expression or tissue-specific gene expression in plants.

TCCACGTGGC

(SEQ ID NO:19)

Combinations between different G-box sequences and Gal4 binding sites can lead to diversity and specificity of plant gene expression in different tissues and organs. The CHS Unit I of the chalcone synthase gene promoter from parsley is a light-inducible element required for specific gene activation in light responsiveness (Weisshaar et al., 1991, *EMBO J.* 10: 1777-1786; Menkens et al., 1995, *TIBS* 20: 506-510). The nucleotides of this element that are recognized as being important for light responsiveness are shown in SEQ ID NOS:20 and 21.

CCACGTGGCC

(SEQ ID NO:20)

GTCCCTCCAACCTAACC

(SEQ ID NO:21).

One or more copies of the CHS Unit I, as shown in SEQ ID NO:22, or a sequence that is essentially similar, especially in combination with the Gal4 binding sites, can be used to increase the level of constitutive gene expression.

5 CCACGTGGCCATCCGGTGGCCGTCCTCCAACCTAACC (SEQ ID NO:22)

Another type of regulatory element that can improve gene activation by the instant two component system is an enhancer element. Any enhancer can be added to the Gal4 binding site promoter, optionally with the RY-G-box-RY element, Gy2 element, Em element, C1
10 element, G-box element, or CHS Unit I element. Examples of enhancers are the AT-rich enhancer from the phaseolin promoter (van der Geest et al., 1994 *The Plant Journal* 6 p 413-423; van der Geest et al., 1997, *Plant Molecular Biology* 33: 553-557), the OCS enhancer from the octopine synthase gene (Greve et al., 1983, *J. of Molecular and Applied Genetics* 1: 499-511), and the enhancer from the Cauliflower Mosaic Virus 35S promoter
15 (Odell et al., 1988, *Plant Molecular Biology* 10:263-272).

Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described more fully in Sambrook, J., Fritsch, E.F. and Maniatis, T. *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter "Maniatis").

20 Plasmid vectors comprising the instant chimeric genes are constructed using conventional techniques well known to those skilled in the art. The choice of plasmid vector is dependent upon the method that will be used to transform host plants and the desired selection markers. The skilled artisan is well aware of the genetic elements that must be present on the plasmid vector in order to successfully transform, select and propagate host
25 cells containing the chimeric gene. The skilled artisan will also recognize that different independent transformation events will result in different levels and patterns of expression (Jones et al., *EMBO J.* 4:2411-2418, 1985; De Almeida et al., *MGG* 218:78-86, 1989), and thus that multiple events must be screened in order to obtain lines displaying the desired expression level and pattern. Such screening may be accomplished using conventional
30 techniques well known to those skilled in the art such as Southern analysis of DNA, Northern analysis of mRNA expression, Western analysis of protein expression, or phenotypic analysis.

The instant invention improves upon the available means of expressing transgenes by providing a method to regulate transgene expression in stably transformed plants. The
35 method of the invention provides a means to achieve 1) a higher expression level than the level expressed from a commonly used, highly expressed seed storage protein gene promoter, 2) activation of expression in the grain following a cross, 3) coordinate regulation of multiple transgenes, and 4) amplification of the expression level while maintaining the expression pattern of a tissue-specific or developmentally regulated promoter.

EXAMPLES

The present invention is further defined in the following Examples, in which all parts and percentages are by weight and degrees are Celsius, unless otherwise stated. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

EXAMPLE 1

Construction of Gal4 binding site promoter-GUS reporter gene

A promoter consisting of four Gal4 binding sites and a phaseolin minimal promoter extending 5' to -65 was constructed 5' to a beta-glucuronidase (GUS) coding region and a phaseolin 3' polyadenylation signal sequence region. The four segments of this chimeric gene called G4G consist of the following: (1) Oligonucleotides containing four copies of the Gal4 DNA binding site consensus sequence as set forth is SEQ ID NO:1 (Brasselman et al., 1993, PNAS 90: 1657) and terminal restriction sites. These oligonucleotides have the sequences shown in SEQ ID NOS:23 and 24.

TCACCGGATCCTACGGAGGACAGTCCTCCGATTTACGGAGGACAGTCCTCCGAA
TATCGATAACGGAGGACAGTCCTCCGATTTACGGAGGACAGTCCTCCGAATTAT
CTGCAGAATAA (SEQ ID NO:23)

TTATTCTGCAGATAATTCGGAGGACTGTCCTCCGTAAATCGGAGGACTGTCCTCC
GTTATCGATATTCGGAGGACTGTCCTCCGTAAATCGGAGGACTGTCCTCCGTAG
GATCCGGTGA (SEQ ID NO:24)

The double stranded DNA fragment resulting from annealing of these two oligonucleotides has a 5' BamHI site and a 3' PstI site. (2) An NsiI-NcoI fragment extending from -65 of the phaseolin promoter to + 77 with respect to the transcription start site. The NcoI site had been added previously (Slightom et al., 1991 Plant Mol Biol Man B16: 1). PstI and NsiI ends anneal and ligate without regenerating a restriction site. (3) An NcoI-EcoRI fragment containing the *uida* coding region (GUS; Jefferson et al., 1987 EMBO J 6: 3901). (4) A 1.2 kb EcoRI-HindIII fragment containing the phaseolin polyadenylation signal sequence region (Slightom et al., 1991 Plant Mol Biol Man B16: 1). The chimeric G4G gene with NotI and XbaI sites added to the 5' BamHI site in plasmid pGEM9Zf is called pG4G (Figure 1).

This chimeric gene was cloned as a BamHI-SalI fragment, after addition of the SalI site 3' to the HindIII site, into the *Agrobacterium tumefaciens* binary vector pZBL1 creating pZBL3. pZBL1 contains the origin of replication from pBR322, the bacterial nptII kanamycin resistance gene, the replication and stability regions of the *Pseudomonas aeruginosa* plasmid pVS1 (Itoh et al., 1984), T-DNA borders described by van den Elzen et al., 1985 wherein the OCS enhancer (extending from -320 to -116 of the OCS promoter; Greve et al., 1983, *Journal of Molecular and Applied Genetics* 1: 499-511) that is a part of the right border fragment is removed, and a Nos/P-nptII-Ocs 3' gene to serve as a kanamycin resistant plant selection marker. Plasmid pZBL1 has been deposited with the ATCC and bears accession number 209128.

A second chimeric gene with Gal4 binding sites in the promoter was constructed identically to G4G with the addition of a DNA fragment located 5' to the four Gal4 binding sites. This additional DNA fragment is derived from the upstream portion of the phaseolin promoter and is the 1.08 kilobase DNA fragment bounded by the EcoRI site at -1471 and the NsiI site at -391, and containing a matrix attachment region and an AT-rich enhancer (obtained from Tim Hall, Texas A&M University; van der Geest et al., 1994 *The Plant Journal* 6 p 413-423, van der Geest and Hall, 1997, *Plant Molecular Biology* 33: 553-557). The partial sequence of this DNA fragment (-890 to -391) is available (GenBank Accession #J01263 M13758) from which a probe can be made to isolate the full EcoRI - NsiI fragment. A PstI (polylinker site) -NsiI fragment containing these sequences was subcloned into the NsiI site of pGEM9Zf vector so that it could be removed as a NotI- XbaI fragment and then added to the G4G gene to create PhG4G. To construct the PhG4G gene in a binary vector, first a BamHI site was added 5' to the PhG4G gene and then the BamHI-BamHI fragment containing the phaseolin promoter upstream sequence (Ph5') was cloned into the BamHI site upstream of the Gal4 sites in the binary pZBL3 vector to form pZBL7. The correct orientation of the Ph5' fragment was confirmed by restriction enzyme analysis.

A control construct, -65-GUS, consisting of a phaseolin -65 minimal promoter fused to the GUS coding region and the phaseolin 3' polyadenylation signal sequence region was made by fusing an Nsi-XbaI fragment containing the phaseolin -65 promoter and GUS coding region with an XbaI-HindIII fragment containing the phaseolin 3' region into the PstI and HindIII sites of the pSP72 vector. This chimeric gene, with no Gal4 sites, was cloned as a BamHI-XhoI fragment into the BamHI and SalI sites in the binary vector pZBL1 to form pZBL2.

EXAMPLE 2

Construction of chimeric Gal4 transcription activators

A chimeric Gal4-PvAlf transcription activator was constructed under control of either a -410 phaseolin promoter (Ph/P-G4Alf) or a 35S promoter-Cab leader (35S-G4Alf). The Ph/P-G4Alf chimeric activator gene has four segments: (1) a 494 bp HindIII-NcoI

fragment of the phaseolin promoter, extending to -410 and including leader sequences to +77 (Slightom et al., 1991 Plant Mol Biol Man B16: 1), (2) an NcoI-SmaI fragment encoding the N-terminal 147 amino acids of the Gal4 DNA binding domain (Ma et al., 1988 Nature 334: 631), (3) a SmaI-SalI fragment encoding the N terminal 243 amino acids of the PvAlf activation domain (Bobb et al., 1995 Plant J 8 p 101-113), (4) a 1.2 kb SalI-HindIII fragment containing the phaseolin 3' sequence. In the 35S-G4Alf chimeric activator gene, a 1.4 kb HindIII-NcoI fragment of the 35S promoter and Cab leader was used to replace the -410 phaseolin promoter and leader sequence in the Ph/P-G4Alf chimeric gene. The CaMV 35S promoter + chlorophyll a/b binding protein (cab) leader includes 35S promoter sequences extending to 8 bp beyond (3' to) the transcription start site operably linked to a 60 bp untranslated leader DNA fragment derived from the cab gene 22L (Harpster et al. 1988 Mol. Gen. Genet 212: 182).

Another chimeric Gal4-VP16 transcription activator was also made under control of either a -410 phaseolin promoter (Ph/P-G4VP16) or a 35S promoter-Cab leader (35S-G4VP16). A 696 bp NcoI-BamHI (BamH I blunted) fragment encoding both the N-terminal 147 amino acids of the Gal4 DNA binding domain and the C-terminal 78 amino acids of the Herpes simplex virus VP16 activation domain (Triezenberg et al., 1988 Genes and Dev. 2: 718) was cloned into the NcoI site and the SmaI site of the Ph/P-G4Alf or 35S-G4Alf to replace the G4Alf segments.

Each chimeric activator gene was first cloned as a HindIII fragment into the HindIII site pSK vector which had a second KpnI site added between the Bam HI and XbaI polylinker sites. The chimeric activator expression cassette was then cut out as a KpnI fragment and cloned into the KpnI site of the binary vector pZ5KAD creating pZ5KAD-Ph/P-G4Alf, pZ5KAD-35S-G4Alf, pZ5KAD-Ph/P-G4VP16, pZ5KAD-35S-G4VP16. The binary vector pZ5KAD contains the origin of replication from PBR322, the bacterial kanamycin nptII resistance gene, the replication and stability regions of the *Pseudomonas* plasmid pVS1 (Itoh et al., 1984), T-DNA borders (van den Elzen et al., 1985), and a 35S/P-ALS^R-ALS 3' gene to serve as a sulfonylurea resistant plant selection marker.

Each binary vector construction was transformed into *Agrobacterium tumefaciens* LBA4404, which was then used to inoculate tobacco leaf tissue. Transgenic tobacco plants were obtained essentially by the procedure of De Blaere et al., 1987 Meth. Enzymol. 143:277. Selection for transformed shoots was on either 20-50 ppb chlorsulfuron or 100 mg kanamycin/l. Shoots were rooted on either 20 mg chlorsulfuron/l or 100 mg kanamycin/l.

35 EXAMPLE 3

Addition of seed-specific RY-G-box-RY regulatory element to Gal4 binding site promoter

Oligonucleotides containing two copies of the RY-G-box-RY element consensus sequence (Conceicao and Krebbers, 1994 Plant J. 5: 493-505; Bustos et al., 1991 EMBO J.

- 10: 1469-1479; Kawagoe et al., 1994 Plant J. 5: 885-890; Bobb et al., 1997 Nucleic Acids Research 25: 641-647; Dickinson et al., 1988, Nucleic Acids Research 16: 371; Fujiwara and Beachy 1994, Plant Molecular Biology 24: 261-272; Chamberland et al., 1992, Plant Molecular Biology 19: 937-949) and terminal restriction BamH I sites were designed. These oligonucleotides have the sequences shown in SEQ ID NOS: 25 and 26.

GATCCTGCATGCATGTCTACACGTGATCGCCATGCAATTTGGCTCACCCCTCGAG
CTGCAGTAGCATGCTTCAGTCTGTTGCATGCATGTCTACACGTGATCGCCATGCA
ATT (SEQ ID NO:25)

GATCAATTGCATGGCGATCACGTGTAGACATGCATGCAACAGACTGAAGCATGC
TACTGCAGCTCGAGGGGTAGGCCAAATTGCATGGCGATCACGTGTAGACATGCA
TGCAG (SEQ ID NO:26)

- The double stranded DNA fragment resulting from annealing of these two oligonucleotides has BamH I sites at both 5' and 3' ends. The 5' BamH I site was a perfect one which can be cut again by BamH I after cloning. The 3' BamH I site can only be used for ligation. The annealed DNA fragment was cloned directly into the BamH I site upstream of the four copies of the Gal4 binding site of G4G to form (RY-G-Box-RY)₂-G4G. The direct orientation of this RY-G-box-RY element upstream of the Gal4 sites was confirmed by BamH I digest. The chimeric (RY-G-box-RY)₂-G4G gene was cloned as a BamHI-Sall fragment into the binary vector pZBL1 creating pZBL4 as described in Example 1.

EXAMPLE 4

Addition of Glycinin 2 regulatory element to Gal4 binding site promoter

- Oligonucleotides containing two copies of the Glycinin 2 (Gy2) element (CACA element plus legumin box) from the glycinin 2 gene of legumes (Lelievre et al., 1992, Plant Physiology 98: 387-391) and terminal restriction BamH I sites were designed. These oligonucleotides have the sequences shown in SEQ ID NOS: 27 and 28.

GATCCGTGTAACACACAAGGCTTCCATAGCCATGCATACTGAAGAATGTCTCAA
TGGCTCACCCCTCGAGCTGCAGTAGCATGCTTCAGTCTGTGTGTAACACACAAG
GCTTCCATAGCCATGCATACTGAAGAATGTCTCAA (SEQ ID NO:27)

GATCTTGAGACATTCTTCAGTATGCATGGCTATGGAAGCCTTGTGTGTTACACAC
AGACTGAAGCATGCTACTGCAGCTCGAGGGGTGAGCCATTGAGACATTCTTCAG
TATGCATGGCTATGGAAGCCTTGTGTGTTACACG (SEQ ID NO:28)

The double stranded DNA fragment resulting from annealing of these two oligonucleotides has BamH I sites at both 5' and 3' ends. The annealed DNA fragment was cloned directly

into the BamH I site upstream of the four copies of the Gal4 binding site in G4G to form (Gy2)₂-G4G as described in Example 3.

EXAMPLE 5

Addition of ABA- and VP1-regulated Em regulatory element to Gal4 binding site promoter

5 Oligonucleotides containing two copies of the Em element consensus sequence (extending from -152 to -78 from the transcription start site of the wheat Em promoter; Marcotte et al., 1989, Plant Cell 1: 969-976; Vasil et al., 1995, Plant Cell 7: 1511-1518) and terminal restriction BamH I sites were designed. These oligonucleotides have the sequences shown in SEQ ID NOS: 29 and 30.

10 GATCCTGCCGGACACGTGGCGCGACAGCAGGGACAACGAGCAGGCCGACGCAC
GTCCGCGTCGCTGCACACGTGCCGCCTTGGCTCACCCTCGAGCTGCAGTAGCA
TGCTTCAGTCTGTTGCCGGACACGTGGCGCGACAGCAGGGACAACGAGCAGGC
CGACGCACGTCCGCGTCGCTGCACACGTGCCGCCT (SEQ ID NO:29)

15 GATCAGGCGGCACGTGTGCAGCGACGCGGACGTGCGTCGGCCTGCTCGTTGTCC
CTGCTGTCGCGCCACGTGTCCGGCAACAGACTGAAGCATGCTACTGCAGCTCGA
GGGGTGAGCCAAGGCGGCACGTGTGCAGCGACGCGGACGTGCGTCGGCCTGCT
CGTTGTCCCTGCTGTCGCGCCACGTGTCCGGCAG (SEQ ID NO:30)

20 The double stranded DNA fragment resulting from annealing of these two oligonucleotides has BamH I sites at both 5' and 3' ends. The annealed DNA fragment was cloned directly into the BamH I site upstream of the four copies of the Gal4 binding site in G4G to form (Em)₂-G4G as described in Example 3. The chimeric (Em)₂-G4G gene was cloned as a
25 BamHI-SalI fragment into the binary vector pZBL1 creating pZBL5 as described in Example 1.

EXAMPLE 6

Addition of ABA- and VP1-regulated C1 regulatory element to Gal4 binding site promoter

30 Oligonucleotides containing two copies of the C1 element (including the GT-element and the SphI element) (Hattori et al., 1992, Gene & Development 6: 609-618; Kao et al., 1996, Plant Cell 8: 1171-1179) and terminal restriction BamH I sites were designed. These oligonucleotides have the sequences shown in SEQ ID NOS: 31 and 32.

35 GATCCGCAGTGTCGTGTCGTCCATGCATGCACTTTTGGCTCACCCTCGAGCTGC
AGTAGCATGCTTCAGTCTGTGCAGTGTGTCGTGTCGTCCATGCATGCACTTT
(SEQ ID NO:31)

40 CATGCTACTGCAGCTCGAGGGGTGAGCCAAAAGTGCATGCATGGACGACACGA
CACGATCAAAGTGCATGCATGGACGACACGACACTGCACAGACTGAAGTGCG
(SEQ ID NO:32)

The double stranded DNA fragment resulting from annealing of these two oligonucleotides has BamH I sites at both 5' and 3' ends. The annealed DNA fragment was cloned directly into the BamH I site upstream of the four copies of the Gal4 binding site in G4G to form (C1)₂-G4G as described in Example 3.

EXAMPLE 7

Addition of constitutive G-box regulatory element to Gal4 binding site promoter

Oligonucleotides containing four copies of the G-box element, TCCACGTGGC (Menkens et al., 1995, TIBS 20: 506-510; Katagiri and Chua, 1992, Trends in Genetics 8: 22-27; Foster and Chua, 1994, FASEB 8: 192-200) and terminal restriction BamH I sites were designed. These oligonucleotides have the sequences shown in SEQ ID NOS: 33 and 34.

GATCCTCCACGTGGCTATTCAATACTCCACGTGGCTGGCTCACCCCTCGAGCTGC
AGTAGCATGCTTCAGTCTGTTCCACGTGGCTTCAAGATTTTCCACGTGGC
(SEQ ID NO:33)

GATCGCCACGTGGAAAATCTTGAAGCCACGTGGAACAGACTGAAGCATGCTACT
GCAGCTCGAGGGGTGAGCCAGCCACGTGGAGTATTGAATAGCCACGTGGAG
(SEQ ID NO:34)

The double stranded DNA fragment resulting from annealing of these two oligonucleotides has BamH I sites at both 5' and 3' ends. The annealed DNA fragment was cloned directly into the BamH I site upstream of the four copies of the Gal4 binding site in G4G to form (G-box)₄-G4G as described in Example 3. The chimeric (G-box)₄-G4G gene was cloned as a BamHI-Sall fragment into the binary vector pZBL1 creating pZBL6 as described in Example 1.

EXAMPLE 8

Addition of light-inducible CHS Unit I regulatory element to Gal4 binding site promoter

Oligonucleotides containing two copies of the CHS Unit I element of the chalcone synthase gene from parsley (including box I and box II; Weisshaar et al., 1991, EMBO J. 10: 1777-1786; Menkens et al., 1995, TIBS 20: 506-510) and terminal restriction BamH I sites were designed. These oligonucleotides have the sequences shown in SEQ ID NOS: 35 and 36.

GATCCCCTTATTCCACGTGGCCATCCGGTGGCCGTCCCTCCAACCTAACCTCCCT
TGTGGCTCACCCCTCGAGCTGCAGTAGCATGCTTCAGTCTGTCCTTATTCCACGT
GGCCATCCGGTGGCCGTCCCTCCAACCTAACCTCCCTTG
(SEQ ID NO:35)

GATCCAAGGGAGGTTAGGTTGGAGGGACGGCCACCGGATGGCCACGTGGAATA
 AGGACAGACTGAAGCATGCATCTGCAGCTCGAGGGGTGAGCCACAAGGGAGGT
 TAGGTTGGAGGGACGGCCACCGGATGGCCACGTGGAATAAGGG (SEQ ID NO:36)

- 5 Each copy of the CHS Unit I element is underlined and conserved nucleotides are in bold type. The double stranded DNA fragment resulting from annealing of these two oligonucleotides has BamH I sites at both 5' and 3' ends. The annealed DNA fragment was cloned directly into the BamH I site upstream of the four copies of the Gal4 binding site in G4G to form (CHS-Unit I)₂-G4G as described in Example 3.

10 EXAMPLE 9

Addition of phaseolin AT-rich enhancer to (RY-G-box-RY)₂-Gal4 binding site promoter

- An additional enhancer DNA fragment was introduced upstream of the (RY-G-box-RY)₂-Gal4 binding sites. As described in Example 1, this AT-rich enhancer was derived from the upstream portion of the phaseolin promoter (Ph5') extending from an
 15 EcoRI site at -1471 to an NsiI site at -391, and containing a matrix attachment region and an AT-rich enhancer (obtained from Tim Hall, Texas A&M University; van der Geest et al., 1994, The Plant Journal 6 p 413-423; van der Geest and Hall, 1997, Plant Molecular Biology 33: 553-557). To construct the Ph5'-(RY-G-Box-RY)₂-G4G gene in a binary vector, the BamHI-BamHI fragment containing Ph5' as described in Example 1 was cloned into the
 20 BamHI site upstream of the (RY-G-box-RY)₂-Gal4 sites in the binary pZBL4 vector to form pZBL8. The correct orientation of the Ph5' fragment was confirmed by restriction enzyme analysis.

EXAMPLE 10

Addition of phaseolin AT-rich enhancer to (Em)₂-Gal4 binding site promoter

- 25 As in Example 9, the phaseolin AT-rich enhancer was also introduced into the (Em)₂-Gal4 binding site promoter-GUS reporter gene. To construct the Ph5'-(Em)₂-G4G gene in a binary vector, the BamHI-BamHI fragment containing Ph5' as described in Example 1 was cloned into the BamHI site upstream of the (Em)₂-Gal4 sites in the binary pZBL5 vector to form pZBL9. The correct orientation of the Ph5' fragment was confirmed
 30 by restriction enzyme analysis.

EXAMPLE 11

Addition of phaseolin AT-rich enhancer to (G-box)₄-Gal4 binding site promoter

- As in Example 9, the phaseolin AT-rich enhancer was also introduced into the (G-box)₄-Gal4 binding site promoter-GUS reporter gene. To construct the
 35 Ph5'-(G-box)₄-G4G gene in a binary vector, the BamHI-BamHI fragment containing Ph5' as described in Example 1 was cloned into the BamHI site upstream of the (G-box)₄-Gal4 sites in the binary pZBL6 vector to form pZBL10. The correct orientation of the Ph5' fragment was confirmed by restriction enzyme analysis.

EXAMPLE 12

Genetic crossing of transgenic tobacco plants

Primary transformants were transferred to soil and grown in a growth chamber maintained for a 14 hr, 21°C day, 10 hr, 18°C night cycle, with approximately 80% relative humidity, under mixed cool white fluorescent and incandescent lights. Plants were grown to maturity and hand pollinations were performed using a slight modification of the procedure by Wernsman, E. A. and D. F. Matzinger in Hybridization of Crop Plants W. R. Fehr and H. H. Hadley, eds, pp 657-668 (1980). Briefly, flowers from plants to be used as the female parents were selected on the day before anthesis; the corolla was split longitudinally, the anthers were removed, and the stigma was pollinated with pollen from flowers from male parent plants that were allowed to anthes on the plant. To prevent contaminating pollen from reaching the stigma, a 4 cm length of a cocktail stirrer, one end plugged with modeling clay, was slipped over the stigma and style and held in place by the corolla. Each flower was tagged. Capsules were allowed to grow to maturity and then harvested.

Genetic crossing was conducted at the R₀ generation (primary transformants) between the effector plants carrying a chimeric transcription factor and reporter plants carrying a Gal4 binding site promoter-GUS gene. Three independent transgenic tobacco plants containing a reporter gene were individually crossed to three independent transgenic lines containing an effector gene. The reporter plants were also crossed to the wild type tobacco plants serving as a control for the gene expression level in the absence of effectors.

EXAMPLE 13

Assay of transgene expression in seed

F₁ seeds from genetic crosses were analyzed for GUS activities. For each sample about 100 seeds (30 mg) were quickly frozen in liquid N₂ and ground in 0.5 ml GUS lysis buffer (50 mM NaH₂PO₄/Na₂HPO₄, pH 7, 10 mM EDTA, 0.1% Triton X-100, 0.1% Sarkosyl, 10 mM b-Mercaptoethanol). Following a 15 min high speed centrifugation at 4°C, the supernatant was collected and stored at -70°C until assayed. For the GUS assay, 25 µl of GUS lysis buffer was first added into each individual well of a 96-well fluorometric microtitre plate (Titretek Fluoroplate; ICN Biomedicals). One microliter of each sample extract was added into the 25 µl of GUS lysis buffer in each well. One hundred and fifty microliters of freshly prepared MUG substrate (1.7 mM 4-methylumbelliferyl-b-D glucuronide (Sigma) in GUS lysis buffer) was added to each well. The reaction was stopped by adding 75 µl of 0.6 M Na₂CO₃ at 0, 30, 60, and 120 minutes after addition of MUG substrate. Fluorescence was detected and quantified using a Perkin-Elmer LS-3B spectrometer. Sample activities were determined from a standard curve constructed by plotting the amount of MU standards (pmol) versus their measured fluorescence intensities. Protein assays were performed on the same sample extracts using the Bio-rad Protein Assay

System (Hercules, CA) following the manufacturer's instructions for the microtitre plate protocol. GUS activities were then calculated as pmol/min/mg protein.

As shown in Figures 9-12, the chimeric G4VP16 and G4Alf transcription factors, under control of either the phaseolin promoter or 35S promoter, specifically activated the Gal4 binding site promoter. This gene activation required specific Gal4 binding sites in the responsive promoters, since gene activation was not detected in the pZBL2 reporter lines, which are the control with no Gal4 sites in the promoter.

For example, in Figure 9 lanes I-L show GUS activities in F₁ seed resulting from crossing pZBL3 line 2A (which carries the reporter gene, i.e., the GUS gene driven by the Gal4 binding site promoter) with plants of either wild type (WT) or Ph/P-G4VP16 lines 14A, 15A, or 13B (which, with the exception of the wild type negative control, carry the chimeric transcription factor under the control of the seed specific phaseolin promoter). Lane I thus shows the background level of expression when no chimeric transcription factor is provided; J-L show the range of expression levels which were obtained with both components of the system present. All are clearly higher than the control, indicating that the chimeric transcription factor is activating transcription above the background level. More crosses were done using three additional pZBL3 transgenic lines. Lanes M-R show the results of crossing reporter lines pZBL3 6A, 4B, and 3D with a single Ph/P-G4VP16 line 14A (lanes N, P, R) and the WT control (lanes M, O, Q). Again the chimeric transcription factor activates GUS expression well above background levels in all crosses.

The specificity of this gene activation system was also demonstrated. Lanes A and B show GUS activities in F₁ seed resulting from crossing a control plant pZBL2 2C (a minimal promoter lacking Gal4 binding sites) with WT or Ph/P-G4VP16 line 14A. Lanes C-F show GUS activities in F₁ seed resulting from crossing a control plant pZBL2 11A with WT or Ph/P-G4VP16 lines 14A, 15A or 13B. Lanes G-H show GUS activities in F₁ seed resulting from crossing a control plant pZBL2 4B with WT or Ph/P-G4VP16 line 14A. With no Gal4 binding sites present no activation is observed.

Figures 10-21 are read in a similar manner as described for Figure 9.

As shown in Figures 13-16, the ABA- and VP1-regulated Em element or constitutively regulated G-box element were also used in combination with the Gal4 binding sites. The chimeric G4VP16 and G4Alf transcription factors, under control of either the phaseolin promoter or 35S promoter, specifically activated the (Em)₂-Gal4 binding site promoter (pZBL5) or the (G-box)₄-Gal4 binding site promoter (pZBL6) used to express the GUS reporter gene in stable transgenic tobacco seeds. As shown in Figure 13, the level of gene activation conferred by combining G-box and Gal4 sites together (pZBL6) is much higher than that obtained from the Gal4 sites alone (pZBL3) (compare the level of GUS activity in lane N in Figure 13 to that in lane N in Figure 9). Lane Q shows the level of GUS activity in seed from a highly expressed Ph/P-GUS line. This is the control Ph/P-GUS line

described earlier (Odell et al., 1994 Plant Phys. 106: 447) containing a -410 phaseolin promoter. Lane R shows GUS activity in seed from a highly expressed 35S-GUS line, which is derived from pZ4loxAG transformants described in Russell et al. 1992 Mol. Gen. Genet. 234: 49. The examples of the two component expression system demonstrated in Figure 13 lane N, as well as in Figure 14 lane O, and Figure 15 lane P, had levels of expression that are higher than that of the phaseolin promoter. Many more examples in these figures had expression that is higher than that of the 35S promoter.

Figures 17-20 show activation of promoters containing an additional AT-rich enhancer from the 5' region of the phaseolin promoter located upstream of the Gal4 sites (pZBL7), the (RY-G-Box-RY)₂-Gal4 sites (pZBL8), the (Em)₂-Gal4 sites (pZBL9), or the (G-box)₄-Gal4 sites (pZBL10). The chimeric G4VP16 and G4Alf transcription factors, under control of either the phaseolin promoter or 35S promoter, specifically activated the Gal4 sites in pZBL7, pZBL8, pZBL9 and pZBL10 to express the GUS reporter gene in stable transgenic tobacco seeds. The level of GUS activities in F₁ seed resulting from crossing pZBL7, pZBL8, pZBL9 or pZBL10 plants to WT plants indicates the background level of expression from the GUS gene constructions in these plants. In the two component Gal4 system that includes seed-specific elements or constitutive elements and an AT-rich enhancer, the regulatory elements function together to further activate gene expression and increase the level of gene expression.

As shown in Figures 9-20, the levels of activation varied in crosses between different transformed lines. The highest activation was achieved when a Ph/P-G4VP16 effector line (14A) or a Ph/P-G4Alf line (17A) was crossed with pZBL9 3F, 4F or pZBL10 11H, 7C reporter lines (Figure 17, lanes L, N, T, Z, Figure 19, lane L). The best gene expression level conferred by this two component Gal4 system in seeds was about 3-fold higher than that conferred by the phaseolin promoter (compare lanes L and A' in Figure 17) and about 15-fold higher than the 35S promoter (compare lanes L and B' in Figure 17). Similar, but a little lower levels of activation were achieved when 35S-G4VP16 and 35S-G4Alf were used as effectors (Figures 18 and 20).

Thus, the two component gene regulation system of the invention which is based on at least one Gal4 binding site and optionally additional regulatory elements, and the Gal4 DNA binding domain, in conjunction with an activation domain, was successful in activating gene expression in seed which harbor both components of the system. The most effective lines were able to direct expression at a 3-fold higher level than that obtained from the highly active phaseolin promoter.

EXAMPLE 14

Assay of transgene expression in seedlings

F₁ tobacco seedlings from the genetic crosses were also analyzed for GUS activities. For each cross analyzed, about 50 seeds were germinated and grown on moistened sand at

room temperature (20°C) under fluorescent lights for 14 days. The seedlings (including both leaf and root tissue) were ground in 1.0 ml GUS lysis buffer. GUS assays and protein assays were done as described above. As shown in Figure 21, both G4Alf and G4VP16, driven by the 35S promoter, specifically activated gene expression in stable transgenic tobacco

5 seedlings. The highest activation levels were achieved in the genetic cross between the 35S-G4VP16 effector lines and the PhG4G 17C reporter line (lanes O, P). The highest gene expression level conferred by this two component Gal4 gene expression system in tobacco seedlings was about the same level as conferred by the 35S promoter (compare lanes P and R). No activation above background was observed when no Gal4 binding sites are provided
10 (-65-5C, lanes A-D). Specific gene activation was obtained in seedlings with 35S-G4Alf but to a less extent (lanes E-L). In all cases it can be seen that the use of different individual transformants for either the reporter or effector line results in differing activation levels. Those skilled in the art will recognize this as the manifestation of "position effects" commonly observed in families of transgenic plants (Jones et al., EMBO J.
15 4:2411-2418, 1985; De Almeida et al., MGG 218:78-86, 1989).

Thus, the two component gene regulation system of the invention which based on at least one Gal4 binding site and optionally additional regulatory elements and the Gal4 DNA binding domain, in conjunction with an activation domain, was successful in activating gene
20 expression in seedlings which harbor both components of the system. The most effective lines were able to direct expression at the same level as obtained from the highly active 35S promoter.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT:
 - (A) ADDRESSEE: E. I. DUPONT DE NEMOURS AND COMPANY
 - (B) STREET: 1007 MARKET STREET
 - (C) CITY: WILMINGTON
 - (D) STATE: DELAWARE
 - (E) COUNTRY: UNITED STATES OF AMERICA
 - (F) ZIP: 19898
 - (G) TELEPHONE: 302-992-5481
 - (H) TELEFAX: 302-773-0164
 - (I) TELEX: 6717325
- (ii) TITLE OF INVENTION: SPECIFIC GENE ACTIVATION BY CHIMERIC GAL4 TRANSCRIPTION FACTORS IN STABLE TRANSGENIC PLANTS
- (iii) NUMBER OF SEQUENCES: 36
- (iv) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: DISKETTE, 3.50 INCH
 - (B) COMPUTER: IBM PC COMPATIBLE
 - (C) OPERATING SYSTEM: MICROSOFT WINDOWS 95
 - (D) SOFTWARE: MICROSOFT WORD VERSION 7.0A
- (v) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vi) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/881,687
 - (B) FILING DATE: JUNE 24, 1997
- (vii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: CHRISTENBURY, LYNNE M.
 - (B) REGISTRATION NUMBER: 30,971
 - (C) REFERENCE/DOCKET NUMBER: BB-1078-A

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: YES
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CGGAGGACAG TCCTCCG

17

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Saccharomyces cerevisiae*
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CGGATTAGAA GCCGCCG

17

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Saccharomyces cerevisiae*
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CGGGTGACAG CCCTCCG

17

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Saccharomyces cerevisiae*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AGGAAGACTC TCCTCCG

17

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Saccharomyces cerevisiae*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CGCGCCGCAC TGCTCCG

17

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Saccharomyces cerevisiae*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CGGACAACTG TTGACCG

17

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 30 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "RY-G-box-RY element"
- (iii) HYPOTHETICAL: YES
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CATGCATGTC TACACGTGAT CGCCATGCAA

30

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (ix) FEATURE:
 - (A) NAME/KEY: misc_binding
 - (B) LOCATION: 1..6
 - (D) OTHER INFORMATION: /function= "CACA box"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

TAACACA

7

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 27 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

TTCCATAGCC ATGCATACTG AATGTCT

27

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CATGCATG

8

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CATGCAAG

8

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CATGCATA

8

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1..7
(D) OTHER INFORMATION: /standard_name= "CACA box"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 14..43
(D) OTHER INFORMATION: /standard_name= "legumin box"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

TAACACACAA GGCTTCCATA GCCATGCATA CTGAAGAATG TCT 43

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GGACACGTGG C 11

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CGAGCAGGC 9

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GCACACGTGC C

11

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 67 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 1..11
 - (D) OTHER INFORMATION: /standard_name= "Em1a element"
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 28..36
 - (D) OTHER INFORMATION: /standard_name= "Em2 element"
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 57..67
 - (D) OTHER INFORMATION: /standard_name= "Em1b element"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GGACACGTGG CGCGACAGCA GGGACAACGA GCAGGCCGAC GCACGTCCGC GTCGCTGCAC

60

ACGTGCC

67

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GTGTCGTGTC GTCCATGCAT GCAC

24

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 2..8
 - (D) OTHER INFORMATION: /standard_name= "G-box motif"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

TCCACGTGGC

10

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: YES
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 2..7
 - (D) OTHER INFORMATION: /standard_name= "G-box element"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

CCACGTGGCC

10

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 2..7

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CGGATTAGAA GCCGCCG

17

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 2..7
- (D) OTHER INFORMATION: /standard_name= "G-box motif"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

CCACGTGGCC ATCCGGTGGC CGTCCCTCCA ACCTAACC

38

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 119 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "oligonucleotide"

(iii) HYPOTHETICAL: NO

(ix) FEATURE:

- (A) NAME/KEY: protein_bind
- (B) LOCATION: 14..30
- (D) OTHER INFORMATION: /bound_moiety= "Gal4 binding domain"

(ix) FEATURE:

- (A) NAME/KEY: protein_bind
- (B) LOCATION: 36..52
- (D) OTHER INFORMATION: /bound_moiety= "Gal4 binding domain"

(ix) FEATURE:

- (A) NAME/KEY: protein_bind
- (B) LOCATION: 64..80
- (D) OTHER INFORMATION: /bound_moiety= "Gal4 binding domain"

- (ix) FEATURE:
(A) NAME/KEY: protein_bind
(B) LOCATION: 86..102
(D) OTHER INFORMATION: /bound_moiety= "Gal4 binding domain"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

TCACCGGATC CTACGGAGGA CAGTCCTCCG ATTTACGGAG GACAGTCCTC CGAATATCGA 60
TAACGGAGGA CAGTCCTCCG ATTTACGGAG GACAGTCCTC CGAATTATCT GCAGAATAA 119

- (2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 119 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"

- (iii) HYPOTHETICAL: NO

- (ix) FEATURE:
(A) NAME/KEY: protein_bind
(B) LOCATION: 18..34
(D) OTHER INFORMATION: /bound_moiety= "Gal4 binding domain"

- (ix) FEATURE:
(A) NAME/KEY: protein_bind
(B) LOCATION: 40..56
(D) OTHER INFORMATION: /bound_moiety= "Gal4 binding domain"

- (ix) FEATURE:
(A) NAME/KEY: protein_bind
(B) LOCATION: 68..84
(D) OTHER INFORMATION: /bound_moiety= "Gal4 binding domain"

- (ix) FEATURE:
(A) NAME/KEY: protein_bind
(B) LOCATION: 90..106
(D) OTHER INFORMATION: /bound_moiety= "Gal4 binding domain"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

TTATTCTGCA GATAATTCGG AGGACTGTCC TCCGTAAATC GGAGGACTGT CCTCCGTTAT 60
CGATATTCGG AGGACTGTCC TCCGTAAATC GGAGGACTGT CCTCCGTAGG ATCCGGTGA 119

- (2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"

(iii) HYPOTHETICAL: NO

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 8..37
(D) OTHER INFORMATION: /standard_name= "RY-G-box-RY
element"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 82..111
(D) OTHER INFORMATION: /standard_name= "RY-G-box-RY
element"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

GATCCTGCAT GCATGTCTAC ACGTGATCGC CATGCAATTT GGCTCACCCC TCGAGCTGCA 60
GTAGCATGCT TCAGTCTGTT GCATGCATGT CTACACGTGA TCGCCATGCA ATT 113

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"

(iii) HYPOTHETICAL: NO

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 7..36
(D) OTHER INFORMATION: /standard_name= "RY-G-box-RY
element"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 81..110
(D) OTHER INFORMATION: /standard_name= "RY-G-box-RY
element"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

GATCAATTGC ATGGCGATCA CGTGTAGACA TGCATGCAAC AGACTGAAGC ATGCTACTGC 60
AGCTCGAGGG GTAGGCCAAA TTGCATGGCG ATCACGTGTA GACATGCATG CAG 113

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 143 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "oligonucleotide"

(iii) HYPOTHETICAL: NO

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 9..51
- (D) OTHER INFORMATION: /standard_name= "Gy2 element"

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 98..140
- (D) OTHER INFORMATION: /standard_name= "Gy2 element"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

GATCCGTGTA ACACACAAGG CTTCCATAGC CATGCATACT GAAGAATGTC TCAATGGCTC	60
ACCCCTCGAG CTGCAGTAGC ATGCTTCAGT CTGTGTGTAA CACACAAGGC TTCCATAGCC	120
ATGCATACTG AAGAATGTCT CAA	143

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 143 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "oligonucleotide"

(iii) HYPOTHETICAL: NO

(ix) FEATURE:

- (A) NAME/KEY: misc_binding
- (B) LOCATION: 8..50
- (D) OTHER INFORMATION: /standard_name= "Gy2 element"

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 97..139
- (D) OTHER INFORMATION: /standard_name= "Gy2 element"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

GATCTTGAGA CATTCTTCAG TATGCATGGC TATGGAAGCC TTGTGTGTTA CACACAGACT	60
---	----

GAAGCATGCT ACTGCAGCTC GAGGGGTGAG CCATTGAGAC ATTCTTCAGT ATGCATGGCT 120
 ATGGAAGCCT TGTGTGTTAC ACG 143

(2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 195 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "oligonucleotide"
- (iii) HYPOTHETICAL: NO
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 10..76
 - (D) OTHER INFORMATION: /standard_name= "Em regulatory element"
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 125..191
 - (D) OTHER INFORMATION: /standard_name= "Em regulatory element"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GATCCTGCCG GACACGTGGC GCGACAGCAG GGACAACGAG CAGGCCGACG CACGTCCGCG 60
 TCGCTGCACA CGTGCCGCCT TGGCTCACCC CTCGAGCTGC AGTAGCATGC TTCAGTCTGT 120
 TGCCGGACAC GTGGCGCGAC AGCAGGGACA ACGAGCAGGC CGACGCACGT CCGCGTCGCT 180
 GCACACGTGC CGCCT 195

(2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 195 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "oligonucleotide"
- (iii) HYPOTHETICAL: NO
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 9..75

(D) OTHER INFORMATION: /standard_name= "Em regulatory element"

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION: 124..190

(D) OTHER INFORMATION: /standard_name= "Em regulatory element"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

GATCAGGCGG CACGTGTGCA GCGACGCGGA CGTGCGTCGG CCTGCTCGTT GTCCCTGCTG	60
TCGCGCCACG TGTCCGGCAA CAGACTGAAG CATGCTACTG CAGCTCGAGG GGTGAGCCAA	120
GGCGGCACGT GTGCAGCGAC GCGGACGTGC GTCGGCCTGC TCGTTGTCCC TGCTGTGCGG	180
CCACGTGTCC GGCAG	195

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 105 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "oligonucleotide"

(iii) HYPOTHETICAL: NO

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION: 9..32

(D) OTHER INFORMATION: /standard_name= "C1 regulatory element"

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION: 79..102

(D) OTHER INFORMATION: /standard_name= "C1 regulatory element"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

GATCCGCAGT GTCGTGTCGT CCATGCATGC ACTTTTGGCT CACCCCTCGA GCTGCAGTAG	60
CATGCTTCAG TCTGTGCAGT GTCGTGTCGT CCATGCATGC ACTTT	105

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 105 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"

(iii) HYPOTHETICAL: NO

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 8..31
(D) OTHER INFORMATION: /standard_name= "C1 regulatory element"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 78..101
(D) OTHER INFORMATION: /standard_name= "C1 regulatory element"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

GATCAAAGTG CATGCATGGA CGACACGACA CTGCACAGAC TGAAGCATGC TACTGCAGCT 60

CGAGGGGTGA GCCAAAAGTG CATGCATGGA CGACACGACA CTGCG 105

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 105 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"

(iii) HYPOTHETICAL: NO

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 6..15
(D) OTHER INFORMATION: /standard_name= "dodecameric G-box element"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 26..35
(D) OTHER INFORMATION: /standard_name= "dodecameric G-box element"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 76..85
(D) OTHER INFORMATION: /standard_name= "dodecameric G-box element"

- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 96..105
 (D) OTHER INFORMATION: /standard_name= "dodecameric G-box element"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

GATCCTCCAC GTGGCTATTC AATACTCCAC GTGGCTGGCT CACCCCTCGA GCTGCAGTAG 60

CATGCTTCAG TCTGTTCCAC GTGGCTTCAA GATTTTCCAC GTGGC 105

- (2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 105 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "oligonucleotide"

- (iii) HYPOTHETICAL: NO

- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 5..14
 (D) OTHER INFORMATION: /standard_name= "dodecameric G-box element"

- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 25..34
 (D) OTHER INFORMATION: /standard_name= "Dodecameric G-box element"

- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 75..84
 (D) OTHER INFORMATION: /standard_name= "dodecameric G-box element"

- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 95..104
 (D) OTHER INFORMATION: /standard_name= "dodecameric G-box element"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

GATCGCCACG TGGAAAATCT TGAAGCCACG TGGAACAGAC TGAAGCATGC TACTGCAGCT 60

CGAGGGGTGA GCCAGCCACG TGGAGTATTG AATAGCCACG TGGAG 105

(2) INFORMATION FOR SEQ ID NO:35:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 149 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "oligonucleotide"
- (iii) HYPOTHETICAL: NO
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 13..50
 - (D) OTHER INFORMATION: /standard_name= "CHS Unit I regulatory element"
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 105..142
 - (D) OTHER INFORMATION: /standard_name= "CHS Unit I regulatory element"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

GATCCCCTTA TTCCACGTGG CCATCCGGTG GCCGTCCCTC CAACCTAACC TCCCTTGTGG	60
CTCACCCCTC GAGCTGCAGT AGCATGCTTC AGTCTGTCCT TATTCCACGT GGCCATCCGG	120
TGGCCGTCCC TCCAACCTAA CCTCCCTTG	149

(2) INFORMATION FOR SEQ ID NO:36:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 149 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "oligonucleotide"
- (iii) HYPOTHETICAL: NO
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 12..49
 - (D) OTHER INFORMATION: /standard_name= "CHS Unit I regulatory element"
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 104..141
 - (D) OTHER INFORMATION: /standard_name= "CHS Unit I regulatory element"


(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

GATCCAAGGG AGGTTAGGTT GGAGGGACGG CCACCGGATG GCCACGTGGA ATAAGGACAG	60
ACTGAAGCAT GCATCTGCAG CTCGAGGGGT GAGCCACAAG GGAGGTTAGG TTGGAGGGAC	120
GGCCACCGGA TGGCCACGTG GAATAAGGG	149

Applicant's or agent's file reference number	BB1078A	International application	Unknown
--	---------	---------------------------	---------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>8</u> , line <u>31</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution AMERICAN TYPE CULTURE COLLECTION	
Address of depositary institution (including postal code and country) 10801 University Blvd. Manassas, Virginia 20110-2209 USA	
Date of deposit 24 June 1997 (24.06.97)	Accession Number 209128
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC)	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g. "Accession Number of Deposit")	
<div style="text-align: center;">For receiving Office use only</div> <input checked="" type="checkbox"/> This sheet was received with the international application <div style="border-top: 1px solid black; padding-top: 5px;">Authorized officer </div>	<div style="text-align: center;">For International Bureau use only</div> <input type="checkbox"/> This sheet was received by the International Bureau on: <div style="border-top: 1px solid black; padding-top: 5px;">Authorized officer</div>

What is claimed is:

1. A method for regulating gene expression in a stably transformed transgenic plant cell which comprises combining into the genome of the plant cell:

a) a first chimeric gene comprising in the 5' to 3' direction:

- 5 (1) a promoter operably linked to at least one Gal4 binding sequence;
(2) a coding sequence or a complement thereof operably linked to the promoter; and
(3) a polyadenylation signal sequence operably linked to the coding sequence or a complement thereof;

10 provided that when the promoter is a minimal promoter then the Gal4 binding sequence is located upstream of the minimal promoter; and

b) a second chimeric gene comprising in the 5' to 3' direction:

- 15 (1) a promoter;
(2) a DNA sequence encoding a DNA binding domain of a Gal4 transcriptional activator;
(3) a DNA sequence encoding a transcriptional activation domain operably linked to the DNA sequence of (2); and
(4) a polyadenylation signal sequence operably linked to the DNA sequence of (3);

20 wherein the expression of the second chimeric gene regulates expression of the first chimeric gene.

2. A method according to Claim 1 wherein the first gene further comprises at least one regulatory element.

25 3. A method according to Claim 1 wherein the first gene further comprises a minimal promoter and at least one regulatory element located upstream of the Gal4 binding sequence.

4. A method according to Claim 2 or 3 wherein the regulatory element is selected from the group consisting of a seed-specific element or a constitutive element.

30 5. A method according to Claim 4 wherein the regulatory element further comprises an enhancer.

6. A method according to Claim 2 or 3 wherein the regulatory element is selected from the group consisting of RY-G-BOX-RY, Em, C1, Gy2, G-Box, CHS Unit 1 or the 5' enhancer of a phaseolin promoter.

35 7. A method according to Claim 1, 2 or 3 wherein first and second constructs are combined into the genome of the plant cell by (a) transforming a plant cell with the first construct, (b) transforming a second plant cell with the second construct, (c) growing fertile mature plants from the transformed plant cells in (a) and (b) and (d) genetically crossing the

transformed plants to produce progeny whose genome contains the first and second constructs.

8. A method according to Claims 1, 2 or 3 wherein the transcriptional activation domain is an acidic transcriptional activation domain.

5 9. A method according to Claims 1, 2 or 3 wherein DNA sequence encoding the transcriptional activation domain is obtained from transcription factors selected from the group consisting of PvAlf or VP16.

10. A transformed plant having at least one gene whose expression is regulated using the method of Claim 1, 2 or 3.

10 11. Seeds obtained from the plant of Claim 10.

1/21




FIG. 1

2/21





FIG. 2

3/21

FIG. 3

SYNTHETIC PROMOTERS: COMBINATION BETWEEN Gal4
ELEMENTS WITH OTHER REGULATORY ELEMENTS



4/21




FIG. 4

5/21




FIG. 5

6/21




FIG. 6

7/21




FIG. 7

8/21

FIG. 8

EXPRESSION OF CHIMERIC GaI4 ACTIVATORS

SEED-SPECIFIC




GaI4 BD VP16 AD



CONSTITUTIVE


35SP/Cab



GaI4 BD VP16 AD



FIG. 10



12/21

FIG. 12





FIG.13



15/21

FIG.15




FIG. 16






FIG. 17



19/21

FIG. 19



20/21

FIG. 20





FIG. 21



INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 98/13006

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/82 C12N5/10 C12N9/24 C07K14/395 C07K14/415
C07K14/035 A01H5/00

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document: with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	AOYAMA, T., ET AL. : "a glucocorticoid-mediated transcriptional induction system in transgenic plants" THE PLANT JOURNAL, vol. 11, no. 3, March 1997, pages 605-612, XP002082422 see the whole document ---	1,2,8-11
X	EP 0 589 841 A (CIBA GEIGY AG) 30 March 1994 pages 5 and page 7, line 47-58; examples 10,14-16; claims ---	1,7-11
X	CA 2 150 039 A (UNIV WARWICK) 9 August 1996 cited in the application page 24, Fig. 4; Fig. 5E; claims --- -/--	1,2,7,8, 10,11

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

5 November 1998

Date of mailing of the international search report

18/11/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Holtorf, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/13006

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MA J ET AL: "YEAST ACTIVATORS STIMULATE PLANT GENE EXPRESSION" NATURE, vol. 334, 18 August 1988, pages 631-633, XP000645136 cited in the application see the whole document ---	1-11
A	BOBB A J ET AL: "PVALF, AN EMBRYO-SPECIFIC ACIDIC TRANSCRIPTIONAL ACTIVATOR ENHANCES GENE EXPRESSION FROM PHASEOLIN AND PHYTOHEMAGGLUTININ PROMOTERS" PLANT JOURNAL, vol. 8, no. 3, 1995, pages 331-343, XP002063683 cited in the application abstract; page 332, left column; page 336, 337-340; Fig.1,4,6,7 ---	1-11
P, X	WO 97 30164 A (MEDICAL RES COUNCIL ; HASELOFF JAMES PHILLIP (GB); HODGE SARAH (GB)) 21 August 1997 pages 2,3,4,5,6; pages 12,13; examples; ; Fig. 2; claims -----	1,2,8-11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/13006

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0589841	A	30-03-1994	US 5409823 A	25-04-1995
			BR 9303877 A	29-03-1994
			CA 2106718 A	25-03-1994
			HU 69965 A	28-09-1995
			MX 9305700 A	31-03-1994
			US 5659124 A	19-08-1997
			US 5824542 A	20-10-1998
CA 2150039	A	09-08-1996	US 5801027 A	01-09-1998
WO 9730164	A	21-08-1997	AU 1801497 A	02-09-1997




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/82, 5/10, 9/24, C07K 14/395, 14/415, 14/035, A01H 5/00		A1	(11) International Publication Number: WO 98/59062
			(43) International Publication Date: 30 December 1998 (30.12.98)
(21) International Application Number: PCT/US98/13006 (22) International Filing Date: 23 June 1998 (23.06.98) (30) Priority Data: 08/881,687 24 June 1997 (24.06.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/881,687 (CON) Filed on 24 June 1997 (24.06.97) (71) Applicant (for all designated States except US): E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): LIU, Zhan-Bin [CN/US]; 108C Presidential Drive, Greenville, DE 19807 (US). ODELL, Joan, Tellefsen [US/US]; 127 Monitor Place, P.O. Box 826, Unionville, PA 19375 (US). (74) Agent: CHRISTENBURY, Lynne, M.; E.I. du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.	


(54) Title: SPECIFIC GENE ACTIVATION BY CHIMERIC GAL4 TRANSCRIPTION FACTORS IN STABLE TRANSGENIC PLANTS

EXPRESSION OF CHIMERIC Gal4 ACTIVATORS

SEED-SPECIFIC



CONSTITUTIVE



(57) Abstract

A method for regulating gene expression in a stably transformed transgenic plant cell utilizing a Gal4 chimeric transcription factor is described.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		